A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

NCT05942625 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy
Focal Segmental Glomerulosclerosis

Interventions

DRUG: HS-10390 tablet
DRUG: Placebo tablet

Sponsor

Hansoh BioMedical R&D Company